期刊文献+

具有抗肿瘤活性的茚并异喹啉类化合物研究进展 被引量:1

Advances on indenoisoquinoline compounds with antitumor activities
下载PDF
导出
摘要 茚并异喹啉是一类具有抗肿瘤活性的化合物,这类化合物可以克服喜树碱类拓扑异构酶Ⅰ(topoisomerase I,Top1)抑制剂的缺陷,获得活性更加稳定、毒性更小的抗肿瘤化合物。近来发现茚并异喹啉类化合物还具有Top1和酪氨酸-DNA磷酸二酯酶(tyrosyl-DNA phosphodiesterase I,Tdp1)双重抑制作用和潜在的肿瘤预防作用。本文简要介绍了Top1抑制剂的作用机制和茚并异喹啉类的作用优势,重点综述了近年来出现的一些茚并异喹啉酮类化合物的构效关系及研究成果。 Indenoisoquinolines are a class of compounds with antitumor activities. The study of indenoisoquino- lines is to overcome the drawbacks of the camptothecins and to obtain compounds with better activities yet less poison. Recently, indenoisoquinolines were also found to have Topl-Tdpl dual inhibition with a potential role in cancer prevention. This review briefly discusses the mechanism of Topl inhibitors and the advantages of indenoisoquinolines with great emphasis on recent developments of indenoisoquinolines and their structure-activity relationships.
出处 《中国药科大学学报》 CAS CSCD 北大核心 2013年第6期589-595,共7页 Journal of China Pharmaceutical University
基金 国家"重大新药创制"科技重大专项资助项目(No.2010ZX09401-401)~~
关键词 茚并异喹啉 拓扑异构酶I抑制剂 抗肿瘤药物 构效关系 研究进展 indenoisoquinoline topoisomerase I inhibitor antitumor drugs structure-activity relationship advances
  • 相关文献

参考文献1

二级参考文献41

  • 1Pommier Y. DNA topoisomerase I inhibitors: chemistry,biology, and interfacial inhibition [ J ]. Chem Rev, 2009, 109 (7) :2894-2902.
  • 2Pommier Y. Topoisomerase I inhibitors:camptothecins and beyond[J]. Nat Rev Cancer,2006,6(10) :789-802.
  • 3Teicher B A. Next generation topoisomerase I inhibitors: rationale and biomarker strategies [ J ]. Biochem Pharma- col,2008,75 (6) : 1262-1271.
  • 4Meng L H, Liao Z Y, Pommier Y. Non-camptothecin DNA topoisomerase I inhibitors in cancer therapy[ J]. Curr Top Med Chem,2003,3 ( 3 ) :305-320.
  • 5Saif M W, Diasio R B. Edotecarin: a novel topoisomerase I inhibitor [ J ]. Clin Colorectal Cancer,2005,5 ( 1 ) : 27-36.
  • 6Hurwitz H I, Cohen R B, McGovren J P, et al. A phase I study of the safety and pharmacokinetics of edotecarin (J- 107088), a novel topoisomerase I inhibitor, in patients with advanced solid tumors [ J ]. Cancer Chernother Phar- macol,2007,59( 1 ) : 139-147.
  • 7Beretta G L, Perego P, Zunino F. Targeting topoisomerase I: molecular mechanisms and cellular determinants of response to topoisomerase I inhibitors [ J ]. Expert Opin Ther Targets ,2008,12 (10) : 1243-1256.
  • 8Ricart A D, Hammond L A, Kuhn J G, et al. Phase I and pharmacokinetic study of sequences of the rebeccamycin analogue NSC 655649 and cisplatin in patients with advanced solid tumors [ J ]. Clin Cancer Res, 2005, 11 (24) : 8728- 8736.
  • 9Sunami S, Nishimura T, Nishimura I, et al. Synthesis and biological activities of topoisomerase I inhibitors, 6-aryl- methylamino analogues of edotecarin [ J ]. J Med Chem, 2009,52(10) :3225-3237.
  • 10Li Z, Zhai F, Zhao L, et al. Design and synthesis of N- methylmaleimide indolocarbazole bearing modified 2-ace- tamino acid moieties as topoisomerase I inhibitors [ J ]. Bioorg Med Chem Lett,2009 ,19 ( 2 ) :406-409.

共引文献2

同被引文献4

引证文献1

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部